The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 24177426.
- Also identified by DOI 10.1172/JCI70972 and PMC identifier 3859399.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Anti-CD20 Ab therapy has proven successful for treating B cell malignancies and a number of autoimmune diseases. However, how anti-CD20 Abs operate in vivo to mediate B cell depletion is not fully understood. In particular, the anatomical location, the type of effector cells, and the mechanism underlying anti-CD20 therapy remain uncertain. Here, we found that the liver is a major site for B cell depletion and that recirculation accounts for the decrease in B cell numbers observed in secondary lymphoid organs. Using intravital imaging, we established that, upon anti-CD20 treatment, Kupffer cells (KCs) mediate the abrupt arrest and subsequent engulfment of B cells circulating in the liver sinusoids. KCs were also effective in depleting malignant B cells in a model of spontaneous lymphoma. Our results identify Ab-dependent cellular phagocytosis by KCs as a primary mechanism of anti-CD20 therapy and provide an experimental framework for optimizing the efficacy of therapeutic Abs.
Medical subject headings
- Antibodies, Monoclonal
- Antigens, CD20
- B-Lymphocytes
- Kupffer Cells
- Liver
- Lymphocyte Depletion
- Lymphoma, B-Cell
- Optical Imaging